Lower factor XII activity is a risk marker rather than a risk factor for cardiovascular disease: A rebuttal

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 6, 2008, Pages 1053-1054

  Kanaji, T ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 12;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CORONARY DISEASE; FACTOR XII; FACTOR XII DEFICIENCY; FACTOR XIIA; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK;

EID: 43749123466     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02949.x     Document Type: Letter

References (14)

1. Bach J, Endler G, Winkelmann BR, Boehm BO, Maerz W, Mannhalter C, Hellstern P. Coagulation factor XII activity, activated factor XII, distribution of factor XII C46T gene polymorphism and coronary risk. J Thromb Haemost 2008; 6: 291-6.
2. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006; 108: 4045-51.
3. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N, Niho Y. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91: 2010-4.
4. Kanaji T, Watanabe K, Hattori S, Urata M, Iida H, Kinoshita S, Kayamori Y, Kang D, Hamasaki N. Factor XII gene (F12) -4C/C polymorphism in combination with low protein S activity is associated with deep vein thrombosis. Thromb Haemost 2006; 96: 854-5.
5. Endler G, Marsik C, Jilma B, Schickbauer T, Quehenberger P, Mannhalter C. Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost 2007; 5: 1143-8.
6. Miller GJ, Esnouf MP, Burgess AI, Cooper JA, Mitchell JP. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol 1997; 17: 2103-6.
7. Colhoun HM, Zito F, Norman Chan N, Rubens MB, Fuller JH, Humphries SE. Activated factor XII levels and factor XII 46C>T genotype in relation to coronary artery calcification in patients with type 1 diabetes and healthy subjects. Atherosclerosis 2002; 163: 363-9.
8. Lowe GD, Rumley A, McMahon AD, Ford I, O'Reilly DS, Packard CJ. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24: 1529-34.
9. Kelleher CC, Mitropoulos KA, Imeson J, Meade TW, Martin JC, Reeves BE, Hughes LO. Hageman factor and risk of myocardial infarction in middle-aged men. Atherosclerosis 1992; 97: 67-73.
10. Altieri P, Devoto E, Spallarossa P, Rossettin P, Garibaldi S, Bertero G, Balbi M, Barsotti A, Brunelli C, Ghigliotti G. Acute coronary syndromes do not promote prolonged in vivo FXII-dependent prothrombotic activity. Thromb Res 2005; 115: 65-72.
11. Dick J, McClaren M, Ford R. The effect of atrovastatin on activated factor XII, fibrinogen and lipid profile. Haemostasis 2000; 30: 30-97.
12. Kushiya F, Wada H, Ooi K, Sakurai Y, Sakaguchi A, Noda M, Abe Y, Nakasaki T, Tsukada T, Shiku H, Nobori T. Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis. Am J Hematol 2005; 78: 1-6.
13. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
14. Braat EA, Dooijewaard G, Rijken DC. Fibrinolytic properties of activated FXII. Eur J Biochem 1999; 263: 904-11.